Swiss biotechnology company Roche Group (SIX: RO, ROG) (OTCQX: RHHBY) announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Roche Digital Pathology Dx (VENTANA DP 200) system.
This enables pathologists to use digital slide images for primary diagnosis, improving healthcare efficiency and patient care, particularly in areas with limited access to specialists.
The system is designed to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
FDA clearance marks a significant step towards routine clinical use of Roche's digital pathology solutions.
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review
FDA grants Regenerative Medicine Advanced Therapy designation to Beacon Therapeutics' laru-zova
AstraZeneca and Daiichi Sankyo's Enhertu approved in US for earlier treatment of breast cancer
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment